Table of Content

1. Key Insights

2. Executive Summary of Metabolic Acidosis

3. SWOT Analysis of Metabolic Acidosis

4. Metabolic Acidosis: Market Overview at a Glance

5. Metabolic acidosis: Disease Background and Overview
5.1. Introduction
5.2. Signs and Symptoms
5.3. Pathogenesis
5.4. Etiology
5.5. Effects of metabolic acidosis on the kidney

6. Diagnosis
6.1. Management of metabolic acidosis in CKD

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 10EM
7.3. Epidemiology Scenario: 10EM
7.3.1. Total Prevalence of CKD patients in the 10EM
7.3.2. Total Prevalence of Metabolic Acidosis in CKD patients of the 10EM
7.3.3. Gender-Specific diagnosed cases of Metabolic Acidosis in the 10 EM
7.3.4. Total Diagnosed Population of Metabolic Acidosis in the 10EM
7.3.5. Total Treated Population of Metabolic Acidosis in the 10EM

8. The United States Epidemiology
8.1. Total Prevalent Population of Metabolic Acidosis in the United States
8.2. Total Diagnosed Population of Metabolic Acidosis in the United States
8.3. Total Treated Population of Metabolic Acidosis in the United States

9. EU-5 Epidemiology
9.1. Germany
9.1.1. Total Prevalent Population of Metabolic Acidosis in Germany
9.1.2. Total Diagnosed Population of Metabolic Acidosis in Germany
9.1.3. Total Treated Population of Metabolic Acidosis in Germany
9.2. France
9.2.1. Total Prevalent Population of Metabolic Acidosis in France
9.2.2. Total Diagnosed Population of Metabolic Acidosis in France
9.2.3. Total Treated Population of Metabolic Acidosis in France
9.3. Italy
9.3.1. Total Prevalent Population of Metabolic Acidosis in Italy
9.3.2. Total Diagnosed Population of Metabolic Acidosis in Italy
9.3.3. Total Treated Population of Metabolic Acidosis in Italy
9.4. Spain
9.4.1. Total Prevalent Population of Metabolic Acidosis in Spain
9.4.2. Total Diagnosed Population of Metabolic Acidosis in Spain
9.4.3. Total Treated Population of Metabolic Acidosis in Spain
9.5. The United Kingdom
9.5.1. Total Prevalent Population of Metabolic Acidosis in the United Kingdom
9.5.2. Total Diagnosed Population of Metabolic Acidosis in the United Kingdom
9.5.3. Total Treated Population of Metabolic Acidosis in the United Kingdom
9.6. Japan Epidemiology
9.6.1. Total Prevalent Population of Metabolic Acidosis in Japan
9.6.2. Total Diagnosed Population of Metabolic Acidosis in Japan
9.6.3. Total Treated Population of Metabolic Acidosis in Japan
9.7. Brazil Epidemiology
9.7.1. Total Prevalent Population of Metabolic Acidosis in Brazil
9.7.2. Total Diagnosed Population of Metabolic Acidosis in Brazil
9.7.3. Total Treated Population of Metabolic Acidosis in Brazil
9.8. China Epidemiology
9.8.1. Total Prevalent Population of Metabolic Acidosis in China
9.8.2. Total Diagnosed Population of Metabolic Acidosis in China
9.8.3. Total Treated Population of Metabolic Acidosis in China
9.9. Mexico Epidemiology
9.9.1. Total Prevalent Population of Metabolic Acidosis in Mexico
9.9.2. Total Diagnosed Population of Metabolic Acidosis in Mexico
9.9.3. Total Treated Population of Metabolic Acidosis in Mexico

10. Unmet Needs

11. Patient Journey of Metabolic Acidosis

12. KOL Views

13. Appendix
13.1. Bibliography
13.2. Report Methodology


15. Disclaimer

 



List of Figures


Figure 1: Mechanisms of acid-mediated tubule interstitial fibrosis in chronic kidney disease (CKD)
Figure 2: Algorithm recommended by the experts for etiological diagnosis of metabolic acidemia metabolic acidosis
Figure 3: Management of chronic metabolic acidosis (MA) in chronic kidney disease using sodium bicarbonate (NaHCO3)
Figure 4: Total Prevalence of CKD patients in the 10EM (2017–2030)
Figure 5: Total Prevalence of Metabolic Acidosis in CKD patients of the 10EM (2017–2030)
Figure 6: Total Diagnosed Population of Metabolic Acidosis in the 10EM (2017–2030)
Figure 7: Gender-Specific diagnosed cases of Metabolic Acidosis in the 10 EM (2017–2030)
Figure 8: Total Treated Population of Metabolic Acidosis in the 10EM (2017–2030)
Figure 9: Total Prevalent Population of Metabolic Acidosis in the United States (2017–2030)
Figure 10: Total Diagnosed Population of Metabolic Acidosis in the United States (2017–2030)
Figure 11: Total Treated Population of Metabolic Acidosis in the United States (2017–2030)
Figure 12: Total Prevalent Population of Metabolic Acidosis in Germany (2017–2030)
Figure 13: Total Diagnosed Population of Metabolic Acidosis in Germany (2017–2030)
Figure 14: Total Treated Population of Metabolic Acidosis in Germany (2017–2030)
Figure 15: Total Prevalent Population of Metabolic Acidosis in France (2017–2030)
Figure 16: Total Diagnosed Population of Metabolic Acidosis in France (2017–2030)
Figure 17: Total Treated Population of Metabolic Acidosis in France (2017–2030)
Figure 18: Total Prevalent Population of Metabolic Acidosis in Italy (2017–2030)
Figure 19: Total Diagnosed Population of Metabolic Acidosis in Italy (2017–2030)
Figure 20: Total Treated Population of Metabolic Acidosis in Italy (2017–2030)
Figure 21: Total Prevalent Population of Metabolic Acidosis in Spain (2017–2030)
Figure 22: Total Diagnosed Population of Metabolic Acidosis in Spain (2017–2030)
Figure 23: Total Treated Population of Metabolic Acidosis in Spain (2017–2030)
Figure 24: Total Prevalent Population of Metabolic Acidosis in the United Kingdom (2017–2030)
Figure 25: Total Diagnosed Population of Metabolic Acidosis in the United Kingdom (2017–2030)
Figure 26: Total Treated Population of Metabolic Acidosis in the United Kingdom (2017–2030)
Figure 27: Total Prevalent Population of Metabolic Acidosis in Japan (2017–2030)
Figure 28: Total Diagnosed Population of Metabolic Acidosis in Japan (2017–2030)
Figure 29: Total Treated Population of Metabolic Acidosis in Japan (2017–2030)
Figure 30: Total Prevalent Population of Metabolic Acidosis in Brazil (2017–2030)
Figure 31: Total Diagnosed Population of Metabolic Acidosis in Brazil (2017–2030)
Figure 32: Total Treated Population of Metabolic Acidosis in Brazil (2017–2030)
Figure 33: Total Prevalent Population of Metabolic Acidosis in China (2017–2030)
Figure 34: Total Diagnosed Population of Metabolic Acidosis in China (2017–2030)
Figure 35: Total Treated Population of Metabolic Acidosis in China (2017–2030)
Figure 36: Total Prevalent Population of Metabolic Acidosis in Mexico (2017–2030)
Figure 37: Total Diagnosed Population of Metabolic Acidosis in Mexico (2017–2030)
Figure 38: Total Treated Population of Metabolic Acidosis in Mexico (2017–2030)
Figure 39: Adverse effects of acute metabolic acidosis
Figure 40: Adverse effects of chronic metabolic acidosis

 

List of Tables


Table 1: Summary of Metabolic Acidosis Market, Epidemiology, and Key Events (2017–2030)
Table 2: Total Prevalence of CKD patients in the 10EM (2017–2030)
Table 3: Total Prevalence of Metabolic Acidosis in CKD patients of the 10EM (2017–2030)
Table 4: Total Diagnosed Population of Metabolic Acidosis in the 10EM (2017–2030)
Table 5: Gender-Specific diagnosed cases of Metabolic Acidosis in the 10 EM (2017–2030)
Table 6: Total Treated Population of Metabolic Acidosis in the 10EM (2017–2030)
Table 7: Total Prevalent Population of Metabolic Acidosis in the United States (2017–2030)
Table 8: Total Diagnosed Population of Metabolic Acidosis in the United States (2017–2030)
Table 9: Total Treated Population of Metabolic Acidosis in the United States (2017–2030)
Table 10: Total Prevalent Population of Metabolic Acidosis in Germany (2017–2030)
Table 11: Total Diagnosed Population of Metabolic Acidosis in Germany (2017–2030)
Table 12: Total Treated Population of Metabolic Acidosis in Germany (2017–2030)
Table 13: Total Prevalent Population of Metabolic Acidosis in France (2017–2030)
Table 14: Total Diagnosed Population of Metabolic Acidosis in France (2017–2030)
Table 15: Total Treated Population of Metabolic Acidosis in France (2017–2030)
Table 16: Total Prevalent Population of Metabolic Acidosis in Italy (2017–2030)
Table 17: Total Diagnosed Population of Metabolic Acidosis in Italy (2017–2030)
Table 18: Total Treated Population of Metabolic Acidosis in Italy (2017–2030)
Table 19: Total Prevalent Population of Metabolic Acidosis in Spain (2017–2030)
Table 20: Total Diagnosed Population of Metabolic Acidosis in Spain (2017–2030)
Table 21: Total Treated Population of Metabolic Acidosis in Spain (2017–2030)
Table 22: Total Prevalent Population of Metabolic Acidosis in the United Kingdom (2017–2030)
Table 23: Total Diagnosed Population of Metabolic Acidosis in the United Kingdom (2017–2030)
Table 24: Total Treated Population of Metabolic Acidosis in the United Kingdom (2017–2030)
Table 25: Total Prevalent Population of Metabolic Acidosis in Japan (2017–2030)
Table 26: Total Diagnosed Population of Metabolic Acidosis in Japan (2017–2030)
Table 27: Total Treated Population of Metabolic Acidosis in Japan (2017–2030)
Table 28: Total Prevalent Population of Metabolic Acidosis in Brazil (2017–2030)
Table 29: Total Diagnosed Population of Metabolic Acidosis in Brazil (2017–2030)
Table 30: Total Treated Population of Metabolic Acidosis in Brazil (2017–2030)
Table 31: Total Prevalent Population of Metabolic Acidosis in China (2017–2030)
Table 32: Total Diagnosed Population of Metabolic Acidosis in China (2017–2030)
Table 33: Total Treated Population of Metabolic Acidosis in China (2017–2030)
Table 34: Total Prevalent Population of Metabolic Acidosis in Mexico (2017–2030)
Table 35: Total Diagnosed Population of Metabolic Acidosis in Mexico (2017–2030)
Table 36: Total Treated Population of Metabolic Acidosis in Mexico (2017–2030)
Table 37: Commonly Prescribed Alkalinizing Agents, Dosages, and Considerations
Table 38: Recommendation according to the GRADE methodology
Table 39: Summary of recommendations